Cephalon’s Nuvigil For Jet Lag Is Pulled Off The Runway; Bipolar Indication Remains On The Horizon
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
After dropping efforts to obtain approval of Nuvigil (armodafinil) for treatment of jet lag disorder, Cephalon is left with one possible new indication for the wakefulness drug: depression associated with bipolar disorder.
You may also be interested in...
Teva’s Nuvigil Label-Expansion Effort Shows No Signs Of Fatigue Even After Bipolar Depression Failure
Attempts to expand armodafinil labeling have also included unsuccessful efforts in schizophrenia and jet lag, but Teva has more indications it would like to try with the wakefulness aid.
Teva’s Nuvigil Label-Expansion Effort Shows No Signs Of Fatigue Even After Bipolar Depression Failure
Attempts to expand armodafinil labeling have also included unsuccessful efforts in schizophrenia and jet lag, but Teva has more indications it would like to try with the wakefulness aid.
Still Seeking New Growth Areas, Cephalon Reassures Investors It Can Continue To Build Nuvigil And Treanda
Cephalon highlighted the life-cycle management of its existing franchises during an R&D day held in New York on Nov. 18, with a focus on Nuvigil and Treanda.